ArticleJournal of contemporary brachytherapy2019

Analysis of quality of life after randomized controlled trial of alpha-1 adrenoceptor antagonist alone and in combination with cyclooxygenase-2 inhibitor in patients who underwent low-dose-rate brachytherapy for prostate cancer.

Yasushi Nakai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.